At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 105 enrolled
Drug / intervention
Cediranib +1 moredrug
Likely dose
Cediranib 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of Cediranib 45mg Versus Placebo Following 12 Weeks of Treatment in Patients With Metastatic or Recurrent Renal Cell Carcinoma Who Have Had no Previous Anti-VEGF Therapy.
In Brief
A Phase 2 clinical trial evaluating Cediranib and Cediranib Placebo for Renal Cell Carcinoma. Completed, enrolled 105 participants across 8 sites in 2 countries.
Detailed Summary
Cediranib is being tested to assess its effectiveness on the growth of kidney cancer tumours and also how well it is tolerated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesNetherlands, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedJan 2007
Primary CompletionMar 2008
Study CompletionOct 2016
TodayJul 2026
First PostedJan 18, 2007
Enrollment StartJan 1, 2007
Primary CompletionMar 1, 2008
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.5 years ago
Interventions
Cediranibdrug
45 mg oral tablet
Cediranib Placebodrug
oral tablet